We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Telix Pharmaceuticals Limited is a biotechnology business based in Australia. Telix Pharmaceuticals shares (TLX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Telix Pharmaceuticals has a trailing 12-month revenue of around $5.2 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
| 52-week range | $1.245 - $6.65 |
|---|---|
| 50-day moving average | $5.5474 |
| 200-day moving average | $4.4983 |
| Target price | $2.2 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.089 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$4.67
| 1 month (2021-07-06) | -15.70% |
|---|---|
| 3 months (2021-05-06) | 18.83% |
| Revenue TTM | $5.2 million |
|---|---|
| Gross profit TTM | $3.2 million |
| Return on assets TTM | -23.64% |
| Return on equity TTM | -60.21% |
| Profit margin | 0% |
| Book value | 0.282 |
| Market capitalisation | $1.6 billion |
TTM: trailing 12 months
We're not expecting Telix Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Telix Pharmaceuticals 's shares have ranged in value from as little as $1.245 up to $6.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Telix Pharmaceuticals 's is 2.3762. This would suggest that Telix Pharmaceuticals 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Everything we know about the Pearl Gull Iron IPO, plus information on how to buy in.
Everything we know about the Zoom2u Technologies IPO, plus information on how to buy in.
Copper Search is expected to go public . Here's how to buy in when the IPO launches.
Everything we know about the Alvo Minerals IPO, plus information on how to buy in.
Everything we know about the Star Minerals Limited IPO, plus information on how to buy in.
Everything we know about the Heavy Mineral Limited IPO, plus information on how to buy in.
Everything we know about the X2M Connect IPO, plus information on how to buy in.
Steps to owning and managing Industrial Minerals shares.
Everything we know about the SSH Group IPO, plus information on how to buy in.
Everything we know about the Iris Metals IPO, plus information on how to buy in.
